Bluejay Diagnostics Closes Private Placement
Analysis based on 10 articles · First reported Jun 02, 2026 · Last updated Jun 06, 2026
The private placement provides Bluejay Diagnostics with significant capital, extending its cash runway and enabling continued investment in FDA approval processes and R&D. This financial injection is likely to be viewed positively by investors, potentially stabilizing or increasing the stock price of Bluejay Diagnostics as it reduces immediate financial risk and supports future growth initiatives.
Bluejay Diagnostics, Inc. announced and subsequently closed a private placement, raising $8.5 million in gross proceeds, with the potential for an additional $15.1 million if warrants are fully exercised. The offering involved the sale of 3,655,917 shares of common stock (or pre-funded warrants) and accompanying series G and H warrants at a purchase price of $2.325 per share. H.C. Wainwright & Co. served as the exclusive placement agent. The net proceeds are intended to extend Bluejay Diagnostics' cash runway into the first quarter of 2027, beyond expected FDA submission, and will be used to fund FDA approval-related activities, research and development, and general working capital needs. The securities were offered under Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D, and Bluejay Diagnostics has agreed to file a resale registration statement with the United States — United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard